Gene Therapy R&D and Revenue Forecasts 2018-2028

世界の遺伝子治療研究開発・収益予測

◆タイトル:Gene Therapy R&D and Revenue Forecasts 2018-2028
◆商品コード:VGN808070
◆調査・発行会社:visiongain
◆発行日:2018年5月
◆ページ数:134
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用)GBP2,699 ⇒換算¥383,258見積依頼/購入/質問フォーム
Five User(5名様閲覧用)GBP2,999 ⇒換算¥425,858見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)GBP4,999 ⇒換算¥709,858見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の遺伝子治療研究開発・収益予測"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、結論などの情報をお届けいたします。

The gene therapy market is projected to grow at a CAGR of 41.1% in the first half of the forecast period. In 2018, the cancer treatment submarket accounted for 68.7% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the second half of the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 134 page report you will receive 72 charts– all unavailable elsewhere.

The 134-page report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Gene Therapy R&D and Revenue Forecasts 2018-2028

Report Scope

• Gene Therapy market forecasts from 2018-2028

• This report assesses the approved gene therapy products in the market and gives revenue to 2028 for Neovasculgen

• Provides qualitative analysis and forecast of the submarket by indication for the period 2018-2028:
• Cancer
• Cardiovascular disorders
• Rare diseases
• Ophthalmological diseases
• Other therapeutic uses

• Profiles leading companies that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics

• Assesses the outlook for the leading gene treatment R&D pipeline for 2018 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with revenue forecasts for six leading agents:
• SPK-RPE65 (Spark Therapeutics)
• Collategene (AMG0001, AnGes MG/Vical)
• Invossa (TissueGene-C, TissueGene Inc/Kolon Life Science)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• GSK2696273 (GlaxoSmithKline)

• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2018 to 2028. SWOT analysis is provided and an overview of regulation of the gene therapy market by leading region given.

• Our study discusses factors that influence the market including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States, the European Union and Japan – overcoming technological and medical challenges to pass clinical trials.

Visiongain’s study is intended for anyone requiring commercial analyses for the gene therapy market. You find data, trends and predictions.

Buy our report today Gene Therapy R&D and Revenue Forecasts 2018-2028: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Rare Diseases, Ophthalmologic Conditions, Other Diseases, Approved Gene therapies, R&D Pipeline Analysis, Gene Therapy Regulations by Region and Leading Players.

【レポートの目次】

1. Report Overview

1.1 Global Gene Therapy Market Overview

1.2 Benefits of This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report

1.5 Who is This Report For?

1.6 Methods of the Study

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to Gene Therapy

2.1 What is Gene Therapy?

2.2 Types of Gene Therapy

2.3 Products Excluded from the Report

2.4 Gene Therapy Vectors

3. Gene Therapy World Market: Leading Treatments and Forecasts, 2017-2028

3.1 The World Market for Gene Therapy: Overview of Products

3.2 Gendicine (rAd-p53) – The First Gene Therapy to Market

3.3 Oncorine: Growth is Hindered by Certain Factors

3.4 Neovasculgen: Russia’s First Gene Therapy

3.4.1 Neovasculgen: Historical Performance and Revenue Forecast, 2017-2028

3.5 Glybera: A Drug with Promise

3.5.1 Glybera: Pricing Ends the Dream to Become a Blockbuster Product

3.6 Strimvelis: Second Gene Therapy for an Inherited Disease Ever to be approved for Sale and the First Corrective Gene Therapy for Children to be Approved Anywhere in the World

3.6.1 Even Big Pharma Struggle in the Rare Disease Space

4. Gene Therapy World Market and Disease Submarkets, 2017-2028

4.1 The Global Market for Gene Therapy Drug Treatments in 2017

4.2 Gene Therapy Market Forecast, 2017-2028

4.3 Gene Therapy for Cancer

4.3.1 Clinical Trials for Cancer

4.3.2 The Cancer Gene Therapy Treatment Submarket Forecast 2017-2028

4.4 Gene Therapy for Rare Diseases

4.4.1 The Rare Disease Treatment Submarket Forecast 2017-2028

4.5 Gene Therapy for Cardiovascular Diseases

4.5.1 The Cardiovascular Disease Treatment Submarket Forecast 2017-2028

4.6 Gene Therapy for Ophthalmologic Diseases

4.6.1 Advanced Stage Gene Therapies for Ophthalmologic Diseases

4.6.2 The Ophthalmologic Disease Treatment Submarket Forecast 2017-2028

4.7 Gene Therapy for Other Diseases

4.7.1 The Other Disease Treatment Submarket Forecast 2017-2028

4.7.2 Changing Market Shares: Cancer Disease Gene Therapies Will Dominate and Become Market Leader

5. R&D Pipeline Analysis and Forecasts, 2017-2028

5.1 Pipeline

5.2 Pipeline Analysis

5.3 Collategene (AMG0001) – AnGes MG/Vical

5.4 BC-819 – BioCancell

5.5 BC-821 – BioCancell

5.6 Lenti-D – Bluebird Bio

5.7 LentiGlobin (LentiGlobin BB305) – Bluebird Bio

5.8 SPK-RPE65 – Spark Therapeutics

5.9 SPK-CHM – Spark Therapeutics

5.10 SPK-FIX – Spark Therapeutics/Pfizer

5.11 SPK-TPP1- Spark Therapeutics

5.12 Invossa (TissueGene-C) – TissueGene Inc/Kolon Life Science

5.13 VM202-DPN – ViroMed

5.14 Important Pipeline Technology Developments

5.15 Clustered regularly interspaced short palindromic repeats (CRISPR)

5.16 The Future of the Gene Therapy Pipeline

6. Companies of Interest in the Gene Therapy Market: Robust Pipelines Will Yield Revenue in the Future

6.1 UniQure- the First Commercial Stage Gene Therapy Company in the West

6.2 Biogen – Focusing on Ophthalmologic and Rare Disease Gene Therapies

6.3 Bluebird Bio: Gene Editing Technology

6.4 Spark Therapeutics- Strong Change to Become the First Company with Marketed Gene Therapy in the US

6.5 Applied Genetic Technologies Corporation: Specialisation in Ophthalmologic Diseases

6.6 Oxford Biomedica: Collaboration as a Strategy

6.7 GenSight Biologics – Novel Mitochondrial Technology Platform

6.8 Gene Therapy and Big Pharma: Collaborations

7. Qualitative Analysis of the Gene Therapy Market, 2018-2028

7.1 SWOT Analysis of the Gene Therapy Treatment Market, 2018

7.2 Strengths: A Vast Pipeline for a Wide Range of Indications

7.3 Weaknesses: Low Patient Populations Cannot Sustain Long-Term Growth

7.4 Opportunities and Threats for the Gene Therapy Drug Market, 2018-2028

7.5 Opportunities: Collaborations and Novel Technologies Will Pave the Way

7.6 Threats: Expensive Drugs with Strict Regulations

7.7 National Markets: Regulation of the Gene Therapy Market

7.7.1 Gene Therapy Regulations: Evolving with the Market

7.7.2 US Regulations: Strict Regulation of a Cautious Market

7.7.3 EU Regulations: One Approval So Far

7.7.4 Japanese Regulations: A Rigorous Process

7.7.5 China Has Highest Gene Sequencing Capacity

8. Conclusions

8.1 The World Gene Therapy Treatment Market: Current World Outlook

8.1.1 Leading Gene Therapy Treatment Submarkets and Products, 2017-2028

8.1.2 Driver for Growth to 2028: A Vast Pipeline of Gene Therapy Products

8.1.3 Leading Regional Markets and Companies: Partnerships Will Achieve Success

8.2 The Future of the Gene Therapy Treatment Market

Associated Visiongain Reports

Visiongain report sales order form

About Visiongain

Visiongain Report Evaluation Form

Table of Tables

Table 1.1 Foreign Currency Exchange Rates Utilised: Exchange Rate to $US, 2015, 2016, and 2017

Table 3.1 Approved Gene Therapies, 2017

Table 3.2 Gene Therapies in Pipeline, 2017

Table 3.3 Neovasculgen Historical Revenue Comparisons, Revenue ($m), AGR (%), 2013-2017

Table 3.4 Neovasculgen Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 4.1 Leading Gene Therapy Drugs by Revenue ($m), 2017

Table 4.2 World Market Forecasts for Gene Therapy Drugs by Indication, Market Sizes ($m), Annual Growth Rates (%), CAGR (%), 2017-2028

Table 4.3 Selected Anti-Angiogenic Gene Therapy Using a Non-Viral Vector, 2017

Table 4.4 Selected Anti-Angiogenic Gene Therapy Using a Retroviral Vector, 2017

Table 4.5 Selected Anti-Angiogenic Gene Therapy Using an Adenoviral Vector, 2017

Table 4.6 Selected Anti-Angiogenic Gene Therapy Using an Adeno-Associated Virus Vector, 2017

Table 4.7 Selected Anti-Angiogenic Gene Therapy Using Lentiviral Vector, 2017

Table 4.8 Global Gene Therapy Clinical Trials by Indication, 2017

Table 4.9 Selected Cancer Gene Therapies in Phase 2 and Phase 3 Clinical Trial Development, 2017

Table 4.10 Selected Cancer Gene Therapies in Phase 1 and Phase 1/2 Clinical Trial Development, 2017

Table 4.11 Global Gene Therapy Market: Revenue ($m) and Market Shares (%) by Indication, 2017

Table 4.12 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028

Table 4.13 Rare Diseases Gene Therapy Pipeline, 2017

Table 4.14 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028

Table 4.15 Cardiovascular Gene Therapy Pipeline, 2017

Table 4.16 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028

Table 4.17 Preclinical Ophthalmologic Pipeline, 2017

Table 4.18 Clinical Ophthalmologic Pipeline, 2017

Table 4.19 Additional Products in the Clinical Ophthalmologic Pipeline, 2017

Table 4.20 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028

Table 4.21 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2017-2028

Table 4.22 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2017-2022

Table 4.23 Global Market Forecast for Gene Therapies by Indication: Market Shares (%), 2023-2028

Table 5.1 Promising Gene Therapies in Development, 2018

Table 5.2 Gene Therapies in Phase 3, 2017

Table 5.3 Collatagene Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 5.4 BC-819 Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table5.5 Lenti-D Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 5.6 SPK-RPE65 Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 5.7 Invossa Forecast, Revenue ($m), AGR (%), CAGR (%), 2017-2028

Table 6.1 uniQure Pipeline, 2017

Table 6.2 Spark Therapeutics Collaborations, 2017

Table 6.3 Selected Big Pharma Collaborations in Gene Therapy, 2017

Table 7.1 Strengths and Weaknesses of the Gene Therapy Drug Treatment Market, 2017

Table 7.2 Gene Therapy Pipeline for Neurodegenerative Diseases, 2017

Table 7.3 Gene Therapy Pipeline for Metabolic Diseases, 2017

Table 7.4 Gene Therapy Pipeline for Musculoskeletal Diseases, 2017

Table 7.5 Gene Therapy Pipeline for Viral Diseases, 2017

Table 7.6 Opportunities and Threats of the Gene Therapy Drug Market, 2017

Table 7.7 Clinical Trials for Standard Drug Development Versus Orphan Drug Development, 2017

Table 8.1 Global Gene Therapy Drug Market Forecasts by Indication: Market Size ($m), Market Share (%), CAGR (%), 2017, 2022 and 2028


Table of Figures

Figure 1.1 Global Gene Therapy Market Segmentation Overview, 2017

Figure 2.1 Vectors Used in Gene Therapy Clinical Trials, 2017

Figure 3.1 Neovasculgen Forecast, Revenue ($m), 2017-2028

Figure 4.1 Gene Therapy World Market Forecast, Market Size ($m), AGR (%), 2017-2028

Figure 4.2 Global Gene Therapy Clinical Trials by Indication, 2017

Figure 4.3 Cancer Gene Therapy Pipeline by Phase of Development, 2017

Figure 4.4 Global Gene Therapy Market: Market Shares (%) by Indication, 2018

Figure 4.5 Global Market Forecast for Cancer Gene Therapies: Revenue ($m), 2017-2028

Figure 4.6 Rare Diseases Gene Therapy Pipeline by Phase of Development, 2017

Figure 4.7 Global Market Forecast for Rare Disease Gene Therapies: Revenue ($m), 2017-2028

Figure 4.8 Cardiovascular Gene Therapy Pipeline by Phase of Development, 2017

Figure 4.9 Global Market Forecast for Cardiovascular Disease Gene Therapies: Revenue ($m), 2017-2028

Figure 4.10 Global Market Forecast for Ophthalmologic Disease Gene Therapies: Revenue ($m), 2017-2028

Figure 4.11 Global Market Forecast for Other Disease Gene Therapies: Revenue ($m), 2017-2028

Figure 4.12 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2022

Figure 4.13 Global Market for Gene Therapy Drugs: Market Shares by Indication (%), 2028

Figure 5.1 Gene Therapies in Clinical Development by Phase, 2017

Figure 5.2 Collategene Forecast, Revenue ($m), 2017-2028

Figure 5.3 BC-819 Forecast, Revenue ($m), 2017-2028

Figure 5.4 Lenti-D Forecast, Revenue ($m), 2017-2028

Figure 5.5 SPK-RPE65 Forecast, Revenue ($m), 2017-2028

Figure 5.6 Invossa Forecast, Revenue ($m), 2017-2028

Figure 5.7 Gene Therapy Market Strategy Analysis

Figure 5.8 Key Take Ways, Challenges and Application of CRISPR Market

Figure 5.9 Impact of CRISPR Technology on the Gene Therapy Market

Figure 8.1 Gene Therapy Drug Treatment Market Forecast by Indication: Market Sizes ($m), 2017, 2022, and 2028

★調査レポート[世界の遺伝子治療研究開発・収益予測] ( Gene Therapy R&D and Revenue Forecasts 2018-2028 / VGN808070) 販売に関する免責事項
[世界の遺伝子治療研究開発・収益予測] ( Gene Therapy R&D and Revenue Forecasts 2018-2028 / VGN808070) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆